Group 1 - The stock price of Graco Inc. (GGG.N) increased by 2.06% from February 6 to February 11, 2026, with a peak price of $95.34 on February 11 and a low of $91.71 on February 10, showing a volatility of 3.93% [1] - On February 10, the stock rose by 1.58% with a trading volume of approximately $99.15 million, while on February 11, it slightly increased by 0.11% to close at $94.32 with a reduced trading volume of $48.55 million, indicating lower trading activity [1] - The commercial equipment services sector rose by 1.62%, outperforming the broader U.S. stock market, as the Dow Jones index fell by 0.13% and the Nasdaq index decreased by 0.15%, providing support for the stock [1] Group 2 - In February 2026, 40% of 15 institutions rated Graco as a buy or hold, with 47% maintaining their positions and 13% reducing or selling their holdings, indicating an increase in bearish sentiment [2] - The target price range for Graco is between $85 and $105, with an average target price of $97, suggesting potential upside from the current stock price [2] - Institutions forecast earnings per share (EPS) of $0.766 for Q4 2025, representing a year-over-year growth of 20.31%, and an EPS of $0.741 for Q1 2026, reflecting a growth of 10.76%, with a steady revenue growth expectation of 6.99% year-over-year for Q1 2026 [2]

Core Viewpoint - Nvidia (NVDA.US) is expected to see significant revenue growth, with Goldman Sachs analysts projecting Q4 FY2025 revenue to reach $67.3 billion, exceeding market expectations [1] Group 1: Revenue and Earnings Projections - Analysts anticipate Nvidia's revenue for Q4 FY2025 will be $67.3 billion, indicating strong performance [1] - The earnings are also expected to surpass market expectations, contributing to positive investor sentiment [1] Group 2: Price Target and Growth Potential - Goldman Sachs has set a price target of $250 for Nvidia, suggesting approximately 35% upside from the closing price on February 6 [1] - The anticipated release of the Rubin GPU in Q3 2026 is expected to significantly boost Nvidia's sales volume in Q4 2026 and beyond, supporting robust growth at least until 2028 [1]

Core Viewpoint - Boston Scientific's revenue growth forecast for 2026 is conservative, leading to a decline in stock price despite strong Q4 performance [1][2][3] Group 1: Financial Performance - The company reported adjusted earnings per share (EPS) of $0.80 for Q4, exceeding analyst expectations of $0.78 [3] - Revenue for Q4 reached $5.29 billion, slightly above the market forecast of $5.28 billion [3] Group 2: Future Guidance - For 2026, the company expects adjusted EPS to be between $3.43 and $3.49, with a midpoint of $3.46, which is below the analyst average estimate of $3.47 [1][2] - The organic revenue growth forecast for 2026 is projected at 10% to 11%, a decrease from the 15.8% growth rate in 2025 [3] - For Q1 2026, the expected adjusted EPS is between $0.78 and $0.80, compared to the analyst consensus of $0.79 [3] Group 3: Strategic Developments - The company is preparing to complete a $14.5 billion acquisition of Penumbra, announced last month [1][2]

Core Viewpoint - The company expects its operating revenue for 2025 to be between RMB 6.68 billion and RMB 6.88 billion, representing a year-on-year growth of 18.91% to 22.47% [1] - For the year 2026, the company anticipates its total operating revenue to be between RMB 8.20 billion and RMB 8.80 billion [1] Summary by Category - **2025 Revenue Forecast** - The projected operating revenue for 2025 is estimated to be between RMB 6.68 billion and RMB 6.88 billion [1] - This forecast indicates a growth rate of 18.91% to 22.47% compared to the previous year [1] - **2026 Revenue Forecast** - The company forecasts its total operating revenue for 2026 to be in the range of RMB 8.20 billion to RMB 8.80 billion [1]

Core Insights - Dell Technologies shares increased by 5% following an update on long-term revenue and profit growth expectations [1] - The company now anticipates fiscal 2026 revenue growth between 7% and 9%, up from a previous forecast of 3% to 4% [1] - For the full year, diluted earnings per share are expected to grow at least 15%, compared to earlier expectations of 8% or better [2]

Core Viewpoint - Novartis is preparing to propose a price reduction plan to President Trump by the end of this month, aiming to address the price disparity of drugs between the U.S. and other industrialized countries [1] Group 1: Financial Outlook - Novartis maintains its revenue growth forecast of 5% from 2024 to 2029, with profit growth expected to outpace revenue growth [1] Group 2: Strategic Preparations - The company has adequately prepared for the 15% tariff imposed by the U.S. on drugs imported from the EU, having significantly increased its inventory in the U.S. to sustain operations until mid-2026 [1]